JP2013542241A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542241A5
JP2013542241A5 JP2013538215A JP2013538215A JP2013542241A5 JP 2013542241 A5 JP2013542241 A5 JP 2013542241A5 JP 2013538215 A JP2013538215 A JP 2013538215A JP 2013538215 A JP2013538215 A JP 2013538215A JP 2013542241 A5 JP2013542241 A5 JP 2013542241A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutically acceptable
acceptable salt
cancer
alkylating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538215A
Other languages
English (en)
Japanese (ja)
Other versions
JP6382516B2 (ja
JP2013542241A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/069976 external-priority patent/WO2012062920A1/en
Publication of JP2013542241A publication Critical patent/JP2013542241A/ja
Publication of JP2013542241A5 publication Critical patent/JP2013542241A5/ja
Application granted granted Critical
Publication of JP6382516B2 publication Critical patent/JP6382516B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538215A 2010-11-12 2011-11-11 抗腫瘍アルカロイドを用いる、組み合わせの治療法 Active JP6382516B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382300.1 2010-11-12
EP10382300 2010-11-12
PCT/EP2011/069976 WO2012062920A1 (en) 2010-11-12 2011-11-11 Combination therapy with an antitumor alkaloid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016092369A Division JP6723815B2 (ja) 2010-11-12 2016-05-02 抗腫瘍アルカロイドを用いる、組み合わせの治療法

Publications (3)

Publication Number Publication Date
JP2013542241A JP2013542241A (ja) 2013-11-21
JP2013542241A5 true JP2013542241A5 (enExample) 2014-12-25
JP6382516B2 JP6382516B2 (ja) 2018-08-29

Family

ID=44936282

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013538215A Active JP6382516B2 (ja) 2010-11-12 2011-11-11 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2016092369A Active JP6723815B2 (ja) 2010-11-12 2016-05-02 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059776A Active JP6724055B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059777A Active JP6724056B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016092369A Active JP6723815B2 (ja) 2010-11-12 2016-05-02 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059776A Active JP6724055B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059777A Active JP6724056B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法

Country Status (24)

Country Link
US (5) US20130266666A1 (enExample)
EP (6) EP2786755A3 (enExample)
JP (4) JP6382516B2 (enExample)
KR (9) KR102452022B1 (enExample)
CN (3) CN103282037B (enExample)
AU (4) AU2011328004C1 (enExample)
BR (4) BR122017028568B1 (enExample)
CA (4) CA2995033C (enExample)
CY (4) CY1117466T1 (enExample)
DK (4) DK2786754T3 (enExample)
ES (4) ES2569180T3 (enExample)
HK (1) HK1202422A1 (enExample)
HR (4) HRP20160361T1 (enExample)
HU (4) HUE027516T2 (enExample)
LT (3) LT2786754T (enExample)
ME (3) ME03408B (enExample)
PL (4) PL2786754T3 (enExample)
PT (3) PT2786754T (enExample)
RS (4) RS58609B1 (enExample)
RU (4) RU2743643C2 (enExample)
SI (4) SI2637663T1 (enExample)
SM (4) SMT201900190T1 (enExample)
TR (2) TR201903859T4 (enExample)
WO (1) WO2012062920A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
AU2017206718B2 (en) * 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof
TW202116783A (zh) * 2019-09-03 2021-05-01 西班牙商瑪製藥股份有限公司 盧比克替定治療惡性間皮瘤
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
CA3158733A1 (en) * 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
WO2022005228A1 (ko) * 2020-07-01 2022-01-06 국립암센터 3-케토아실 coa 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
CN118576599A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
IL308389A (en) * 2021-05-19 2024-01-01 Pharma Mar Sa Dosing regimens for acubactadine
CN115957188A (zh) * 2021-06-17 2023-04-14 中国医学科学院医药生物技术研究所 米铂脂质体在抗耐药性肿瘤的应用
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof
WO2024188978A1 (en) * 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
TW202547503A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之ｐｍ１４和拓樸異構酶ｉ抑制劑的組合
WO2025228597A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer
CN120501841B (zh) * 2025-05-21 2026-05-08 广州爱索达生物医药技术有限公司 一种降低化疗治疗副作用的外泌体组合物及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
IL139607A0 (en) 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USAGE AND SYNTHESIS THEREOF
KR100886496B1 (ko) 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
SE0102232L (sv) * 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
EA200500234A1 (ru) * 2002-08-19 2005-08-25 Пфайзер Продактс Инк. Комбинированная терапия гиперпролиферативных болезней
CN101077885A (zh) 2002-10-18 2007-11-28 马尔药品公司 新型抗肿瘤化合物
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
MXPA06013902A (es) * 2004-05-28 2007-01-26 Pfizer Prod Inc Procedimiento para tratar el crecimiento de celulas anormal.
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
ES2374828T3 (es) * 2004-12-15 2012-02-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinaciones de agentes terapéuticos para el tratamiento del cáncer.
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid

Similar Documents

Publication Publication Date Title
RU2013126630A (ru) Комбинированная терапия противоопухолевым алкалоидом
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
JP2011520921A5 (enExample)
JP2007277240A5 (enExample)
JP2024527974A5 (enExample)